Introduction: Alzheimer's disease models (ADMs) are currently used for drug development
(DD). More than 20,000 molecules were screened for AD treatment over decades, with only …

Alzheimer's disease (AD) is a polygenic/complex disorder in which genomic, epigenomic,
cerebrovascular, metabolic, and environmental factors converge to define a progressive …

There is a well‐known relationship between the cholinergic system and learning, memory,
and other common cognitive processes. The process for researching and developing new …

In Alzheimer's disease (AD), approximately 10–20% of direct costs are associated with
pharmacological treatment. Pharmacogenomics account for 30–90% variability in …

Epigenetics is a discipline that studies potentially reversible heritable changes in gene
expression with no structural modifications in the DNA sequence. The epigenetic machinery …

According to the classic definition of aging we share, it is a combination of changes in an
organism leading to an increase in the probability of its death (rate of mortality). 1–4 It should …

The pharmacoepigenetic apparatus is integrated by gene clusters of different categories,
including (i) pathogenic genes involved in disease pathogenesis,(ii) mechanistic genes …

ABSTRACT Introduction Neuropsychiatric disorders (NPDs)(neurodevelopmental, mental,
neurodegenerative, neurotoxic, complex disorders) are the third major problem of health in …

Alzheimer's disease (AD) is a priority health problem in developed countries with a high cost
to society. Approximately 20% of direct costs are associated with pharmacological treatment …

Glaucoma constitutes the second cause of blindness worldwide and it is considered a
neurodegenerative disorder. In this sense, Alzheimer's disease, which is the most common …